CATEGORY
Clinical Trials
Beroe LiVE.Ai™
AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Clinical Trials.
Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.
Category Alerts
Care Access Acquires Brazil Research Site
July 04, 2022Alcon to Acquire Aerie Pharmaceuticals
August 29, 2022Emmes Acquires Clinical Edge
October 06, 2022Become a Beroe LiVE.Ai™ Subscriber to receive proactive alerts on Clinical Trials
Clinical Trials Market Monitoring Dashboard
Understand the correlation between costs, margins, and prices impacting your category on a real time basis on Beroe LiVE.Ai™
Clinical Trials Industry Benchmarks
Savings Achieved
(in %)
The average annual savings achieved in Clinical Trials category is 10.00%
Payment Terms
(in days)
The industry average payment terms in Clinical Trials category for the current quarter is 67.5 days
Compare your category performance against peers and industry benchmarks across 20+ parameters on Beroe LiVE.Ai™
Category Strategy and Flexibility
Engagement Model
Supply Assurance
Sourcing Process
Supplier Type
Pricing Model
Contract Length
SLAs/KPIs
Lead Time
Supplier Diversity
Targeted Savings
Risk Mitigation
Financial Risk
Sanctions
AMEs
Geopolitical Risk
Cost Optimization
Price per Unit Competitiveness
Specification Leanness
Minimum Order Quality
Payment Terms
Inventory Control
The World’s first Digital Market Analyst
Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions
Clinical Trials Suppliers

Find the right-fit clinical trials supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.



Use the Clinical Trials market, supplier and price information for category strategy creation and Quaterly Business Reviews (QRBs)
Clinical Trials market report transcript
Clinical Trials Global Market Outlook:
Market Growth:
Global Clinical Research Organisation Market - $42.3 billion in 2020E
CAGR – 7.6%
Market Drivers:
- Increased focus of pharma on large molecule therapy, rare diseases, specialty treatment, point of care assays, and personalized therapy & devices
- Greater investment in technology and data
CRO Market Size
- The global CRO market was estimated at $42.3 billion in 2020E, and it is expected to grow at a CAGR of 7.6% percent to reach $49.9 billion by 2022F
- This is due to the increased outsourcing seen from the pharmaceutical and biotechnology companies, with 85 percent comprised by the clinical segment
- The focus of CROs have increased onto various post approval commercial offerings owing to increased development in technology and data analysis
- Although spend on specialty focus, such as rare diseases, personalized medicines, and specialty oncology, has increased, the larger portfolio by spend size would continue to drive the programmatic CRO market
CRO Market Drivers
Cost Containment:
Pharmaceutical companies one of the major factors is to reduce costs, by lowering their internal capacities in manufacturing and R&D. This leads to expenses being diverted toward outsourcing, making CROs play an integral part of pharma to increase their productivity, access new capabilities, shift fixed to variable costs, and improve their global reach
RealWorld – Data and Analytics:
As regulators and payers place increasing importance on RWD, pharma is seen to partner with CRO, to support with predictive modeling, analytics, etc. This is driving CROs to either acquire or partner with specialists in this area
Emerging Markets:
The emerging markets of Brazil, China, Russia are witnessing increased trials, creating demand for regional CROs, with strong
regulatory knowledge
New areas of Research and Regulations:
The increased focus of pharma on large molecule therapy, rare diseases, specialty treatment, point of care assays, and personalized therapy & devices will require clinical trial testing and submission of data to the relevant regulatory authorities
Also, the depth of regulatory scrutiny has increased, such as early RWD collection and reporting every adverse events, driving increased clinical trials
Examples: Offshoring of HEOR, pharmacovigilance services to India offer cost saving of ~30–45 percent
Sustainability:
Pharma companies are highly focussed on enhancing sustainability by energy conservation, waste management and green manufacturing. Green Chemistry improves the efficiency of research and development and manufacturing practices, improving safety, saving money and lessening our impact on the environment.